Osteoporosis is a major and growing public health concern. Approximately one in two women and one in five men, aged 50 and older, will experience an osteoporotic fracture \[[@B1]\]. Fractures are associated with reduced independence, increased risk of future fractures, and increased morbidity and mortality \[[@B2], [@B3]\]. Effective prevention and treatment of osteoporosis and fractures are of paramount importance.

The overarching goal of treating osteoporotic patients is to prevent incidence of fractures. Osteoporosis treatment is achieved through either inhibition of bone resorption and/or stimulation of bone formation. To date, antiresorptive agents (*e.g.*, bisphosphonates, denosumab, estrogen, and raloxifene) are the most commonly used therapies for the treatment of osteoporosis. Through diverse mechanisms, antiresorptive agents suppress osteoclastic-mediated bone breakdown and bone turnover \[[@B4]\]. Conversely, osteoanabolic agents promote new bone formation by activation of osteoblasts and bone remodeling \[[@B5]\].

Teriparatide and abaloparatide are currently the only two approved anabolic agents for the treatment of osteoporosis in the United States. The US Food and Drug Administration (FDA) approved teriparatide in 2002 and abaloparatide in 2017. Both agents reduce the incidence of vertebral and nonvertebral fractures \[[@B6], [@B7]\]. A third agent, romosozumab, has remained under evaluation by the FDA, given concerns regarding increased cardiovascular events \[[@B8]\].

The aims of this review are to discuss the mechanism of action, clinical use, and major clinical studies of anabolic drugs for the treatment of osteoporosis. Relevant studies were selected after a PubMed search through December 2017 and included at least one of the following keywords: anabolic, bone mineral density (BMD), fracture, teriparatide, abaloparatide, and romosozumab. Articles of potential interest were then reviewed in full. Additional articles were identified from those publications' references.

1. Mechanism of Action {#s1}
======================

PTH and PTHrP are encoded by related genes and bind to the same receptor, PTH 1 receptor (PTH1R) \[[@B9]\]. PTH (1-84) is an 84-amino acid polypeptide, and PTHrP (1-34) is a 34-amino acid polypeptide. PTH is secreted by the parathyroid gland and plays a fundamental role in calcium homeostasis. PTH increases serum calcium concentrations via promotion of osteoclast-mediated calcium release from bone, distal renal tubular calcium reabsorption, and intestinal calcium absorption. PTHrP is produced by many different tissues and exerts its effects via paracrine actions. Like PTH, PTHrP stimulates bone resorption and renal tubular calcium reabsorption, but in contrast to PTH, PTHrP plays a minor, if any, role in intestinal calcium absorption. PTHrP is additionally involved in fetal calcium regulation, placental calcium transfer, and lactation \[[@B10], [@B11]\].

Teriparatide and abaloparatide, like PTH and PTHrP, enact their effects via binding to PTH1R. Teriparatide, recombinant human PTH \[PTH (1-34)\], comprises the first 34 amino acids of the *N*-terminal end of PTH. Abaloparatide \[PTHrP (1-34)\] is a 34-amino acid synthetic analog of PTHrP that is identical to PTHrP at amino acids 1-22 but differs in amino acids 23-34. These differences were intentionally constructed to maximize the stability and anabolic activity of abaloparatide \[[@B12]\]. Abaloparatide shares 76% homology with PTHrP and 41% homology with PTH \[[@B12]\].

Whereas continuous exposure to PTH or PTHrP results in increased bone resorption, intermittent administration of PTH (1-34) or PTHrP (1-34) leads to an anabolic window and enhanced bone formation \[[@B13]\]. To date, it is not completely understood why the continuous vs intermittent exposure to PTH/PTHrP causes differing effects on bone.

PTH1R has two conformations: RG and R0. The RG conformation results in a shorter intracellular signaling response than the R0 conformation and is believed to result in more anabolic activity. Abaloparatide has a higher selectivity for the RG and a lower selectivity for the R0 conformation than teriparatide and has been hypothesized to have more potent effects on bone formation with lesser effects on bone resorption and lower rates of inducing hypercalcemia \[[@B7], [@B9]\].

2. Clinical Use, Dosing, and Monitoring {#s2}
=======================================

Osteoanabolic treatment should be considered in four main groups of individuals: (1) severe osteoporosis or high risk of fracture, (2) failure of alternative osteoporosis agents while adherent to treatment (fracture or loss of BMD), (3) intolerability or contraindications to other osteoporosis agents, and (4) glucocorticoid-induced osteoporosis \[[@B6], [@B7], [@B14]\]. Available data discussed below show that anabolic therapies produce greater increases in bone density when they are administered before antiresorptive medications. However, anabolic agents are not generally advocated as the first line for the treatment of osteoporosis, given their substantial cost.

Before the commencement of anabolic agents, it is important to exclude secondary causes of osteoporosis, and it is prudent to obtain serum calcium, albumin, phosphorus, creatinine, alkaline phosphatase, and 25-hydroxyvitamin D levels. Treatment with PTH/PTHrP analogs is contraindicated in patients with hypercalcemic disorders. PTH/PTHrP analogs should additionally not be used in anyone with primary or secondary hyperparathyroidism or anyone at increased risk for osteosarcoma (*e.g.*, history of Paget disease, radiation involving the skeleton, bone metastases). PTH/PTHrP analogs should be avoided in individuals with a history of renal stones. It is recommended to assess for underlying hypercalciuria with a 24-hour urine calcium (urinary calcium excretion \>400 mg/24 h), as both teriparatide and abaloparatide can exacerbate hypercalciuria \[[@B7]\]. Patients who are vitamin D deficient should be replaced until vitamin D stores are ≥30 ng/dL before initiation of treatment.

Teriparatide \[PTH (1-34)\] is administered as a 20-µg daily subcutaneous injection into the thigh or abdomen. A 28-dose, prefilled pen is available and requires refrigeration. The 2017 *Institute for Clinical and Economic Review* quoted the wholesale acquisition cost of one pen of teriparatide at \$2998, with an annual cost of \$35,976, although discounts of 30% to 40% were possible \[[@B17]\]. Abaloparatide \[PTHrP (1-34)\] is administered as an 80-µg daily subcutaneous injection into the periumbilical region. Abaloparatide is available in a 30-dose, prefilled pen, which in contrast, does not require refrigeration between doses. The 2017 wholesale acquisition cost of one pen of abaloparatide was ∼\$1625, with an annual cost of \$19,500, although again, discounts were possible \[[@B17]\]. Teriparatide and abaloparatide are also being evaluated for transdermal application \[[@B12]\]. The initial dose of both teriparatide and abaloparatide should be given with the patient sitting or lying in a monitored setting in the event of orthostatic hypotension. Thereafter, the patient can self-administer injections at home.

There are currently no official guidelines on monitoring for the development of hypercalcemia. Importantly, serum calcium should be drawn 24 hours after the last injection. If hypercalcemia does develop, then the first step is reduction in calcium and/or vitamin D supplementation. If hypercalcemia persists (serum calcium \>11.0 mg/dL), then anabolic dosing can be adjusted to every other day, and if it still present, PTH/PTHrP treatment should be discontinued. Likewise, there is no consensus on frequency of BMD monitoring, but dual energy x-ray absorptiometry is typically performed at the start of treatment and again after 1 to 2 years on therapy.

Cumulative use of abaloparatide and teriparatide is restricted to a maximum of 2 years. Use is limited, given that clinical trials did not exceed 2 years, as well as concerns regarding the theoretical risk of increased rates of osteosarcoma observed in rodent models.

3. Clinical Efficacy of Teriparatide {#s3}
====================================

The seminal 2001 Fracture Prevention Trial demonstrated that treatment with teriparatide treatment of at least 18 months significantly reduced the risk of vertebral and nonvertebral fractures in postmenopausal women with osteoporosis. The trial randomized 1637 postmenopausal women with a previous vertebral fracture to a subcutaneous injection of teriparatide 20 µg/d, teriparatide 40 µg/d, or placebo \[[@B6]\]. The study was terminated early, at 21 months, to investigate concerns regarding development of osteosarcomas in Fischer rats during a toxicology study, although no increased risk in humans has been found \[[@B18]\]. After 18 months, treatment with teriparatide resulted in dose-dependent increases in BMD at the spine and hip. Notably, BMD, at the distal radius and shaft of the radius, actually decreased with teriparatide. Both the 20- and 40-µg/d doses of teriparatide resulted in reduced rates of vertebral fractures. There was a 4% incidence of vertebral fracture in the teriparatide 20-µg/d group, 5% in the teriparatide 40-µg/d group, and 14% in the placebo group, representing a risk reduction of 65% in the teriparatide 20-µg group and 69% in the teriparatide 40-µg group compared with placebo. Nonvertebral fractures occurred in 3% in each of the teriparatide groups vs 6% in the placebo group, a risk reduction of 53% in the teriparatide 20-µg group and 54% in the teriparatide 40-µg group compared with placebo \[[@B6]\]. Of note, Kaplan-Meier incidence curves for nonvertebral fracture did not begin to diverge between teriparatide and placebo until 9 to 10 months into treatment \[[@B6]\]. There was no statistically significant difference in fracture reduction between the two doses of teriparatide, but higher rates of hypercalcemia developed at the 40-µg/d dose \[[@B6]\].

Teriparatide has also shown efficacy in osteoporotic men. Men (437) with low spine or hip BMD were randomized to daily injections of teriparatide 20 µg, teriparatide 40 µg, or placebo. The study was also stopped early, after a median duration of 11 months, because of the development of osteosarcomas in rats. At the end of follow-up, spine BMD increased by 5.9% and 9% above baseline in the 20- and 40-µg groups, respectively, and femoral neck BMD increased by 1.5% and 2.9% above baseline in the 20- and 40-µg groups, respectively \[[@B21]\].

Additionally, teriparatide is effective for glucocorticoid-induced osteoporosis. In a 36-month, randomized, controlled trial, 428 men and women with osteoporosis, who had received ≥5 mg/d of a prednisone equivalent for ≥3 months, were randomized to either teriparatide or alendronate. Mean BMD at the lumbar spine increased more (11% vs 5.3%), and fewer new vertebral fractures occurred (1.7% vs 7.7%) in the teriparatide group than in the alendronate group \[[@B14]\].

4. Clinical Efficacy of Abaloparatide {#s4}
=====================================

A phase 2, 24-week trial randomized 222 postmenopausal women with osteoporosis to abaloparatide 20, 40, or 80 µg/d, teriparatide 20 µg/d, or placebo. Abaloparatide, at both the 40- and 80-µg doses significantly increased BMD at the lumbar spine, femoral neck, and total hip compared with placebo. Radius BMD was not reported. No statistically significant difference in lumbar spine BMD was noted between teriparatide and abaloparatide. In contrast, substantial improvements in total hip BMD were seen with abaloparatide compared with teriparatide \[[@B22]\].

In the phase 3 Abaloparatide Comparator Trial in Vertebral Endpoints (ACTIVE) trial, 2463 postmenopausal women were randomized to 18 months of daily subcutaneous injections of abaloparatide 80 µg, open-label teriparatide 20 µg, or placebo. Participants were aged 49 to 86 years and had either BMD T-scores of −3.0 or below or a history of fractures with a BMD T-score of −2.5 or below. Vertebral fractures occurred in 0.58% of participants in the abaloparatide group and in 4.22% in the placebo group, a risk reduction in the abaloparatide group of 86%. Nonvertebral fractures occurred in 2.7% in the abaloparatide group compared with 4.7% in the placebo group, a difference that just met statistical significance. Whereas not a primary endpoint, no statistically significant difference in vertebral fractures was found between teriparatide and abaloparatide \[[@B7]\].

5. Clinical Efficacy of Romosozumab {#s5}
===================================

Romosozumab is currently under review by the FDA for approval. Romosozumab was developed after the 2001 finding that sclerosteosis, a rare genetic disorder with high bone mass, was associated with a loss-of-function mutation in the SOST gene that encodes sclerostin \[[@B23]\]. Sclerostin is produced by osteocytes and both inhibits bone formation and enhances bone resorption. Romosozumab is a humanized monoclonal antibody to sclerostin. The phase 3 Fracture Study in Postmenopausal Women with Osteoporosis (FRAME) trial randomized 7180 subjects to monthly subcutaneous injections of romosozumab 210 mg or placebo for 12 months, followed by an additional 12 months of denosumab in both groups. Participants were women, 55 to 90 years of age with BMD T-scores between −3.0 and −5.0. After 12 months of treatment with romosozumab or placebo, new vertebral fractures occurred in 0.5% of women in the romosozumab group and 1.8% of women in the placebo group, representing a risk reduction of 75% \[[@B24]\].

In the Active-Controlled FRAME at High Risk, 4093 postmenopausal women with osteoporosis and a fragility fracture were randomly assigned to receive monthly subcutaneous romosozumab or weekly oral alendronate for 12 months, followed by alendronate for 12 months in both groups. Over a period of 24 months, new vertebral fractures occurred 6.2% in the romosozumab-to-alendronate group compared with 11.9% in the alendronate-to-alendronate group, representing a 48% lower risk of new vertebral fractures in the romosozumab-to-alendronate group. There was a 27% lower risk of clinical fractures and 38% lower risk of hip fractures. However, during year one, serious cardiovascular adverse events were observed more often with romosozumab than with alendronate \[[@B8]\]. Fifty patients (2.5%) in the romosozumab group and 38 patients (1.9%) in the alendronate group had adjudicated serious cardiovascular adverse events. This contrasts with the FRAME trial, where the incidence of cardiovascular events was balanced between the groups \[[@B8]\]. One possible explanation could be a role for sclerostin in aortic vascular smooth muscle, as some studies have shown SOST expression \[[@B25]\]. Given concerns for increased cardiovascular events, approval for romosozumab remains pending.

6. Head-to-Head Comparisons {#s6}
===========================

There have been very few trials that have compared one anabolic agent with another or an anabolic with an antiresorptive ([Table 1](#T1){ref-type="table"}). A study from Langdahl *et al.* \[[@B26]\], published in 2017, compared changes in BMD after 12 months of romosozumab or teriparatide in women with postmenopausal osteoporosis who had previously received at least 3 years of bisphosphonate therapy. Mean percentage changes in areal BMD from baseline at the total hip, femoral neck, and lumbar spine were significantly greater in the romosozumab group than in the teriparatide group at both 6 and 12 months. At 12 months, those in the romosozumab group had gained 2.9% in BMD at the total hip, 3.2% at the femoral neck, and 9.8% at the lumbar spine compared with −0.5% at the total hip, −0.2% at the femoral neck, and 5.4% at the lumbar spine for those randomized to teriparatide \[[@B26]\]. The ACTIVE trial randomized participants to abaloparatide, open-label teriparatide, or placebo. Whereas the primary outcome compared abaloparatide with placebo, a secondary outcome compared rates of nonvertebral fractures with abaloparatide and teriparatide. There were nonvertebral fractures in 2.7% in the abaloparatide group compared with 3.3% in the teriparatide group, but this difference did not reach statistical significance \[[@B7]\]. An exploratory end-point showed greater improvements in BMD with abaloparatide than those with teriparatide at the total hip and femoral neck at 6, 12, and 18 months and at the lumbar spine at 6 and 12 months but not at 18 months \[[@B7]\].

###### 

Major Trials in Osteoanabolic Treatment

  Trial Name                                  Study Population                                                                                                                Study Drugs                                                                                                            Fracture Reduction
  ------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Fracture Prevention Trial \[[@B6]\]         Postmenopausal women (1637) with ≥1 vertebral fractures                                                                         \(1\) Teriparatide 20 µg/d, (2) teriparatide 40 µg/d, or (3) placebo ×21 mo                                            Vertebral fractures occurred in 4% in the teriparatide 20 µg/d, 5% in the teriparatide 40 µg/d, and 14% in the placebo group, representing a risk reduction of 65% in teriparatide 20 µg group and 69% in teriparatide 40 µg group compared with placebo. Nonvertebral fractures occurred in 3% in each of the teriparatide groups vs 6% in the placebo group. Nonvertebral fracture risk reduction of 53% and 54% in 20 µg and 40 µg groups, respectively.
  ACTIVE \[[@B7]\]                            Postmenopausal women (2463) with T-score ≤−2.5 or T-score ≤−2.0 and ≥2 mild or ≥1 moderate vertebral or nonvertebral fracture   \(1\) Abaloparatide 80 µg/d, (2) teriparatide (open label) 20 µg/d, or (3) placebo ×18 mo                              Vertebral fractures occurred in 0.58% in the abaloparatide group and 4.22% in the placebo group, a risk reduction of 86%. Nonvertebral fractures occurred in 2.7% in the abaloparatide group compared with 4.7% in the placebo group, a risk reduction of 43%.
  Romosozumab Treatment in FRAME \[[@B24]\]   Postmenopausal women (7180) with T-score −2.5 to −3.5 at hip or spine                                                           \(1\) Romosozumab 210 mg monthly or (2) placebo ×12 mo, followed by denosumab 60 mg every 6 mo ×12 mo in both groups   New vertebral fractures occurred in 0.5% of women in the romosozumab group and 1.8% of women in the placebo group. Risk reduction of 75% in vertebral fractures and no substantial risk reduction in nonvertebral fractures compared with placebo.

Whereas there have been only a few studies comparing anabolic with antiresorptive treatment, anabolic treatment was generally superior. New vertebral fractures were the primary outcome of the study, Effects of Teriparatide and Risedronate on New Fractures in Post-Menopausal Women with Severe Osteoporosis (VERO) (see Kendler *et al.* \[[@B27]\]). Among postmenopausal women with severe osteoporosis, risk of new vertebral fractures was significantly lower in those who received teriparatide (5.4%) than risedronate (12%), whereas nonvertebral fracture incidence was not statistically different \[[@B27]\]. Romosozumab was directly compared with alendronate in the Active-Controlled FRAME at High Risk. In postmenopausal women with osteoporosis, who were high risk for fracture, romosozumab treatment of 12 months, followed by alendronate, resulted in a significantly lower risk of vertebral and nonvertebral fractures than alendronate alone \[[@B8]\]. Teriparatide was compared with alendronate for treatment of glucocorticoid-induced osteoporosis, and teriparatide resulted in greater increases in BMD and fewer new vertebral fractures than alendronate \[[@B14]\].

7. Safety and Tolerability {#s7}
==========================

Overall, teriparatide and abaloparatide are well tolerated. However, there are no long-term safety data with abaloparatide. Hypercalcemia and hypercalciuria are the two most common side-effects, although clinically substantial elevations rarely occur \[[@B6], [@B7]\].

In the 2001 Fracture Prevention Trial, teriparatide compared with placebo resulted in greater dizziness (9% vs 6%), leg cramps (3% vs 1%), and hypercalcemia (11% vs 2%) \[[@B6], [@B28]\]. The majority of incidences of hypercalcemia were \<1 mg/dL above the laboratory's reference range. Women who did not develop hypercalcemia within the first 6 months of teriparatide seldom developed hypercalcemia thereafter. Orthostatic hypotension rarely occurred after the initial dose \[[@B6]\].

In a phase 2 trial among 222 postmenopausal women, abaloparatide was well tolerated. The incidence of headache (14% vs 7%) and dizziness (9% vs 4%) was slightly higher in the abaloparatide 80-µg group compared with placebo. Abaloparatide had a significantly lower incidence of hypercalcemia compared with teriparatide \[[@B22]\]. In the phase 3 ACTIVE trial of abaloparatide, the most common adverse events leading to study drug discontinuation were nausea (1.6%), dizziness (1.2%), and headache (1.0%). Again, the frequency of hypercalcemia was lower for abaloparatide than teriparatide (3.4% vs 6.4%) \[[@B7]\]. Increases in uric acid have also been demonstrated with use of both teriparatide and abaloparatide \[[@B29]\].

The most concerning adverse event is the theoretical increased risk of osteosarcoma. Teriparatide and abaloparatide carry a black-box warning for risk of osteosarcoma. This black-box warning derives from evidence that a higher proportion of Fischer rats that was administered PTH (1-34) from 8 weeks to 2 years of age at doses 4 to 28 times human exposure developed higher rates of osteosarcoma \[[@B18], [@B19]\]. The occurrence of osteosarcoma was dose dependent, and the tumors developed after PTH (1-34) had already induced osteosclerosis. In prior studies involving nearly 1000 humans, treatment with PTH (1-84), PTH (1-34), or PTH (1-38) for up to 3 years did not increase the incidence of bone tumors \[[@B20]\]. Furthermore, no relationship has been demonstrated between elevated PTH in the context of hyperparathyroidism and the occurrence of osteosarcoma in humans \[[@B30]\]. There have only been three reported cases of osteosarcoma among the more than one million worldwide patients who have received teriparatide, a rate that does not exceed the expected incidence of osteosarcoma in the general population \[[@B31]\].

8. Combination Therapy With Anabolics {#s8}
=====================================

Studies that combine teriparatide and bisphosphonates have generated inconsistent results. Most have demonstrated no additional benefit of combination teriparatide with bisphosphonates and have even shown some blunting of the anabolic response to PTH \[[@B29], [@B32], [@B33]\]. However, one study, combining a single dose of zoledronic acid with a daily injection of teriparatide, increased spine and hip BMD more than either agent alone \[[@B33]\].

The Denosumab and Teriparatide Administration study evaluated the efficacy of the combination denosumab and teriparatide over denosumab or teriparatide monotherapy. Denosumab is a monoclonal antibody that blocks the binding of receptor activator of nuclear factor κB ligand to its receptor, an interaction that is required for osteoclast formation, activation, and survival \[[@B34]\]. One hundred postmenopausal women with osteoporosis were assigned to receive teriparatide 20 µg/d, denosumab 60 mg every 6 months, or both. After 12 months, BMD at the lumbar spine increased more in the combination group (9.1%) than either the teriparatide (6.2%) or denosumab (5.5%) group alone. Femoral neck and total hip BMD also increased more in the combination group. Although at present, there are no data on fracture outcomes, teriparatide and denosumab administered together could be useful to treat patients at highest risk of fracture \[[@B35]\].

9. Sequence of Anabolic Therapy {#s9}
===============================

The sequence in which anabolic and antiresorptive therapies are instituted impacts the skeletal response. Alendronate given before and concurrently with teriparatide attenuated the BMD and bone-turnover improvement compared with those who received teriparatide alone \[[@B36]\]. However, antiresorptive therapy, administered after an anabolic agent, consolidated the anabolic bone density gains. In the absence of subsequent antiresorptive treatment, BMD benefits will gradually wane, as bone loss has been reported to decline at a rate of up to 4% per year \[[@B37], [@B38]\]. With the use of alendronate or denosumab after teriparatide treatment, BMD benefits persisted or increased \[[@B39]\].

In the preplanned extension of the Denosumab and Teriparatide Administration trial, women who were originally assigned to 24 months of teriparatide received 24 months of denosumab, women who originally received 24 months of denosumab received 24 months of teriparatide, and women who initially received both drugs received an additional 24 months of denosumab alone. The switch from teriparatide or combination therapy to denosumab further increased BMD, whereas the switch from denosumab to teriparatide resulted in a transient loss of BMD and bone microarchitecture \[[@B42]\]. This raises concern for the use of teriparatide after denosumab and suggests that the combination of teriparatide and denosumab, followed by denosumab alone, may be the most potent treatment of severe osteoporosis.

The ACTIVExtend trial, an extension of ACTIVE, enrolled patients who completed 18 months of abaloparatide or placebo to receive up to 24 months of weekly alendronate. The extension trial is still ongoing, but the 6-month follow-up results reported that use of abaloparatide, followed by alendronate, further improved BMD and reduced fracture risk, although the absolute number of fractures was small \[[@B43]\]. These findings suggest that alendronate therapy can preserve the fracture-reduction benefits of abaloparatide.

10. Fracture Healing {#s10}
====================

There is growing evidence to suggest a role for teriparatide in the management of fracture healing. Teriparatide is not currently FDA approved for the treatment of fracture healing but has been used "off license" by many clinicians. There are numerous preclinical studies that have demonstrated that PTH enhances fracture healing \[[@B44]\]. However, the sparse, randomized, controlled human studies have been conflicting. In a randomized, controlled, pilot study in 12 premenopausal women with lower extremity stress fractures, teriparatide vs placebo for 8 weeks produced a substantial anabolic window, and more women on teriparatide (83.3%) vs placebo (57.1%) had improved or healed stress fractures, but this latter difference was not statistically significant \[[@B48]\]. A prospective, randomized, double-blind study of 102 postmenopausal women who had undergone conservative management of distal radial fractures showed shorter time to healing after administration of teriparatide 20 µg/d compared with placebo (9.1 vs 7.4 weeks), although there was no substantial difference between the teriparatide 40-µg/d dose and placebo \[[@B49]\]. An additional study among 40 women with proximal humerus fractures observed no improvement in fracture-healing time with teriparatide \[[@B50]\]. Further studies are needed to assess the efficacy of teriparatide or abaloparatide in the setting of fracture healing.

11. Conclusions {#s11}
===============

Anabolic agents are highly effective at increasing BMD and reducing incidence of both vertebral and nonvertebral fractures. Currently, teriparatide \[PTH (1-34)\] and abaloparatide \[PTHrP (1-34)\] are the only two approved anabolic agents, although at the time of this publication, a third agent, romosozumab, is under review by the FDA. Anabolic therapy is recommended for severe cases of osteoporosis or when alternative options are not available or not tolerated. Given that use of anabolic treatment is limited to 2 years, it should always be followed by antiresorptive treatment. Emerging research suggests a potential role of anabolic agents in the treatment of delayed fracture healing, although more randomized, placebo-controlled studies are needed.
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